Drug treatment, remdesivir – an anti-viral medicine that has been used against Ebola, appears to shorten recovery time for people with coronavirus is being made available on the NHS. Health Secretary Matt Hancock said it was probably the biggest step forward in the treatment of coronavirus since the crisis began. UK regulators say there is
A collection of some of the biggest global pharmaceutical companies have assembled to improve the detection of drug side effects. The Drug Safety Research Unit (DSRU) established the international group which comprises pharma giants such as Pfizer, Roche, BMS, Takeda, Lilly, Gilead, Alexion and Celgene to explore improved ways of identifying adverse side effects from
Although there have been various warnings about the supply train issues that will happen if a so-called “hard Brexit” occurs, the UK and EU have been unable to refine terms on how drugs will move amongst countries. As a result the NHS is also having to scramble to figure out how to mitigate possible drug
The UK government has announced an innovative medicines review and increased funding for the life sciences sector. The Innovative Medicines and MedTech Review has been created to see how new approaches to the development of drugs, diagnostics and devices, “based on precision medicine and emerging technologies, could speed up access to innovative products for NHS
GlaxoSmithKline (GSK) are constructing their first new manufacturing facility in the UK for nearly forty years, in Ulverston, Cumbria, as part of an investment of over £500 million to increase production of active ingredients. GSK currently hires 15,000 people in the UK with almost 6,000 working in manufacturing. The drugs giant announced today that succeeding
New internet resources supported by the UK’s National Institute for Health Research (NIHR) aim to explain paediatric trials for children and their parents, emphasise informed consent, and inform clinical research professionals about what really matters to young trial participants. The websites have been launched as two new sections of the experiential health websites www.healthtalkonline.org and
The reactions from AstraZeneca’s announcement earlier this week that approximately 7,300 jobs would be cut by the end of 2014 has continued, and it appears that the organisation’s UK research staff will be reduced by between 250 and 350 positions. AstraZeneca, the UK’s second biggest drugs maker, currently employs around 61,000 people globally, 8,000 of
